2007
DOI: 10.1016/j.metabol.2007.04.007
|View full text |Cite
|
Sign up to set email alerts
|

Serum concentration of visfatin in obese women

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

9
96
4
1

Year Published

2007
2007
2016
2016

Publication Types

Select...
7
1

Relationship

1
7

Authors

Journals

citations
Cited by 111 publications
(110 citation statements)
references
References 13 publications
9
96
4
1
Order By: Relevance
“…The use of a more specific assay for visfatin/NAMPT determination showed that its level is not associated with glucose and insulin levels. This observation is inconsistent with our previously published data obtained with EIA 14 and supports the hypothesis that visfatin/NAMPT should be considered as a marker of inflammation not directly involved in the homeostasis of glucose metabolism.…”
Section: Number Of Ms Componentscontrasting
confidence: 99%
See 1 more Smart Citation
“…The use of a more specific assay for visfatin/NAMPT determination showed that its level is not associated with glucose and insulin levels. This observation is inconsistent with our previously published data obtained with EIA 14 and supports the hypothesis that visfatin/NAMPT should be considered as a marker of inflammation not directly involved in the homeostasis of glucose metabolism.…”
Section: Number Of Ms Componentscontrasting
confidence: 99%
“…[11][12][13] Increased circulating visfatin/ NAMPT levels have also been reported in subjects diagnosed with obesity and those with MS criteria. 14,15 However, the association between visfatin/NAMPT levels and severity of MS understood as a number of its components has not been assessed so far. In addition, during the analysis of the published studies assessing visfatin/NAMPT levels, we noticed that most of them, including some of our own, estimated visfatin/NAMPT levels with the use of low specific C-terminal enzyme immunoassays (EIA developed by Phoenix Pharmaceuticals, Burlingame, California, United States) or radioimmunoassays, which reported the circulating levels of undefined protein with a molecular weight of ~500 kDa improperly considered as visfatin/NAMPT.…”
mentioning
confidence: 99%
“…In contrast, negative correlations between visfatin concentrations and LDL-cholesterol [40], HDLcholesterol and triglyceride [41] levels were reported. Zahorska-Markiewicz did not observe a correlation between visfatin concentrations and lipids in both the obese and lean groups [37]. The lack of correlation between visfatin levels and parameters of lipid metabolism in the FDRs group warrants further study.…”
Section: Discussionmentioning
confidence: 71%
“…Circulating visfatin concentration in relation to obesity is controversial [27,28,37,38]. In a recent study [39], visfatin/PBEF/Nampt mRNA levels were not correlated with measures of obesity, and the researchers suggested that visfatin is not predominantly secreted from visceral fat.…”
Section: Discussionmentioning
confidence: 99%
“…Although, visfatin is linked to insulin receptors, the link is in a separate location from insulin and by binding to these receptors, it causes reduction in glucose release from the liver and stimulates glucose uptake in adipose cells and muscles (8). Plasma concentration of visfatin is increased in obese subjects (9,10) and those with type 2 diabetes (11). According to reports, an increase in insulin levels may be a compensatory mechanism for defects in insulin action (12).…”
Section: Introductionmentioning
confidence: 99%